Results 231 to 240 of about 1,754,713 (289)
Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer. [PDF]
Shaver AL +5 more
europepmc +1 more source
Hormonal signaling in glioblastoma: emerging roles in stemness and tumor plasticity. [PDF]
García-Sánchez J +2 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Recent Developments in Androgen Receptor Antagonists
Archiv Der Pharmazie, 2015The androgen receptor (AR), a ligand‐dependent transcription factor that regulates the expression of a series of downstream target genes after the binding of androgens, has been a target for the discovery of drugs used to treat prostate cancer. Prostate cancer always progresses to castration‐resistant prostate cancer after a period of androgen ...
Daoguang Zhang +2 more
exaly +3 more sources
Classification and Virtual Screening of Androgen Receptor Antagonists
Journal of Chemical Information and Modeling, 2010Computational tools, such as quantitative structure-activity relationship (QSAR), are highly useful as screening support for prioritization of substances of very high concern (SVHC). From the practical point of view, QSAR models should be effective to pick out more active rather than inactive compounds, expressed as sensitivity in classification works.
Jiazhong Li, Paola Gramatica
openaire +3 more sources
2010
Androgen receptor (AR) antagonists used clinically include steroidal (cyproterone acetate) and nonsteroidal antagonists (bicalutamide, flutamide, and nilutamide), with the latter nonsteroidal compounds being the only ones in general use in the United States. AR antagonists are used as single agents or in conjunction with surgical or medical castration (
Howard C. Shen +2 more
openaire +1 more source
Androgen receptor (AR) antagonists used clinically include steroidal (cyproterone acetate) and nonsteroidal antagonists (bicalutamide, flutamide, and nilutamide), with the latter nonsteroidal compounds being the only ones in general use in the United States. AR antagonists are used as single agents or in conjunction with surgical or medical castration (
Howard C. Shen +2 more
openaire +1 more source
Peptide Antagonist of the Androgen Receptor
Current Pharmaceutical Design, 2010Androgen receptor (AR) is a steroid hormone receptor that is activated by endogenous androgens, mainly testosterone and 5alpha-dihydrotestosterone (5alpha-DHT). AR is also an important drug target, and AR antagonists (antiandrogens) have been widely used for prostate cancer therapy.
openaire +2 more sources
Advances in the computational development of androgen receptor antagonists
Drug Discovery Today, 2020The androgen receptor is a ligand-dependent transcriptional factor and an essential therapeutic target for prostate cancer. Competitive binding of antagonists to the androgen receptor can alleviate aberrant activation of the androgen receptor in prostate cancer.
Xueping Hu +7 more
openaire +2 more sources

